eXmoor Pharma & Anthony Nolan Partner to Advance Cell Therapy Development

eXmoor Pharma, a UK-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, has entered a strategic partnership with Anthony Nolan Cell Therapy & Laboratory Services (CT&LS), a leader in cellular starting materials, to provide an integrated solution for cell therapy developers. The collaboration combines eXmoor’s manufacturing expertise with Anthony Nolan’s donor sourcing and apheresis capabilities, aiming to streamline the development of autologous and allogeneic cell therapies.

The partnership offers an end-to-end service, covering donor recruitment, screening, apheresis collection, process development, and good manufacturing practice (GMP) production. By aligning their complementary strengths, the two organizations seek to support clients in navigating the complex journey from starting material to clinical supply while prioritizing patient and donor welfare.

Anthony Nolan’s CT&LS brings a donor register of over 900,000 HLA-typed individuals, expertise in donor matching and bioinformatics, a cord blood collection program, and a new apheresis center in Nottingham. With more than 50 years of experience, the organization emphasizes high standards of donor care to ensure reliable and scalable material supply. eXmoor Pharma, based in Bristol, will process these materials at its clinical GMP facility, which offers integrated process development, fill-finish, and manufacturing services. The facility has met the ethical standards of Anthony Nolan’s review board, ensuring alignment in operational and ethical practices.

“We are proud to partner with Anthony Nolan’s CT&LS, powered by a UK institution with unmatched expertise in donor services and ethical sourcing,” said Lucy Foley, CEO of eXmoor Pharma. “Together, we can offer cell therapy developers a truly integrated path from donor to patient. This partnership reinforces our commitment not only to technical excellence but also to ethical responsibility, keeping both donors and patients at the centre of everything we do.”

David Bennett, Director of Business Development for Anthony Nolan’s Cell Therapy and Lab Services, added: “As the cell and gene therapy industry evolves, collaboration becomes more important. Our 50+ years of experience in working with donors and our large and diverse register, make Anthony Nolan’s CT&LS the obvious choice for partners like eXmoor who are looking to accelerate therapy development. I’m hugely excited for this new partnership to provide a seamless service for cell and gene therapy developers, facilitating innovation by leveraging our combined expertise in sourcing material and manufacturing.”

The partnership aims to reduce development timelines and complexity while adhering to rigorous clinical and ethical standards, positioning eXmoor and Anthony Nolan as key players in the growing cell therapy market.